2025年06月05日 星期四 首页   |   期刊介绍   |   编 委 会   |   投稿指南   |   期刊订阅   |   广告合作   |   联系我们   |   ENGLISH
哈尔滨医药  2023, Vol. 43 Issue (5): 7-9    DOI: 10.3969/j.issn.1001-8131.2023.05.003
  论著 本期目录 | 过刊浏览 | 高级检索 |
氨溴索联合莫西沙星在老年慢阻肺急性加重期治疗中的应用
李书俊
河南省驻马店市中心医院,河南 驻马店 463000
Application of Ambroxol Combined with Moxifloxacin In The Treatment of Elderly Patients with Chronic Obstructive Pulmonary Disease in Acute Exacerbation
Li Shujun
Henan Zhumadian Central Hospital,Henan 463000,China
全文: PDF (284 KB)   HTML (1 KB) 
输出: BibTeX | EndNote (RIS)      
摘要 目的 探讨氨溴索联合莫西沙星在老年慢阻肺急性加重期(AECOPD)治疗中的疗效。方法 将AECOPD共计80例患者纳入研究,根据治疗方法将采用莫西沙星+常规治疗纳入对照组(40例),将莫西沙星+氨溴索+常规治疗纳入观察组(40例),两组均治疗12d。比较两组治疗前、治疗12d的血清炎性因子水平[C-反应蛋白(CRP)、降钙素原(PCT)];比较两组咳嗽、咳痰、肺部湿啰音消失时间及治疗期间的不良反应发生率。结果 两组治疗12d的CRP、PCT水平均比治疗前下降,且观察组降幅更大(P<0.05);观察组治疗期间咳嗽、咳痰及肺部湿啰音比对照组消失时间短(P<0.05);两组不良反应发生率比较(P>0.05)。结论 氨溴索联合莫西沙星可有效减轻AECOPD患者的炎症反应,缓解临床症状,且不增加不良反应。
服务
把本文推荐给朋友
加入我的书架
加入引用管理器
E-mail Alert
RSS
作者相关文章
李书俊
关键词 慢性阻塞性肺疾病急性加重期氨溴索莫西沙星炎症因子不良反应    
AbstractObjective To investigate the efficacy of ambroxol combined with moxifloxacin in the treatment of elderly patients with acute exacerbation of chronic obstructive pulmonary disease(AECOPD).Methods A total of 80 patients with AECOPD were included in the study.According to the treatment method,moxifloxacin+conventional treatment were included in the control group(40 cases),and moxifloxacin+ambroxol+conventional treatment were included in the observation group(40 cases).Both groups were treated for 12 days.The levels of serum inflammatory factors [C-reactive protein(CRP)and procalcitonin(PCT)] before and after 12 days of treatment were compared between the two groups;The disappearance time of cough,sputum and lung moist rales and the incidence of adverse reactions during treatment were compared between the two groups.Results The levels of CRP and PCT in the two groups decreased after 12 days of treatment compared with those before treatment,and the decrease in the observation group was greater(P<0.05);The disappearance time of cough,expectoration and lung moist rales in the observation group was shorter than that in the control group(P;The incidence of adverse reactions was compared between the two groups(P>0.05).Conclusion Ambroxol combined with moxifloxacin can effectively alleviate the inflammatory reaction and clinical symptoms of AECOPD patients,without increasing adverse reactions.
Key wordsAcute exacerbation of chronic obstructive pulmonary disease    Ambroxol    Moxifloxacin    Inflammatory factors    Adverse reactions
收稿日期: 2022-09-28     
PACS:  R563.5  
引用本文:   
李书俊. 氨溴索联合莫西沙星在老年慢阻肺急性加重期治疗中的应用[J]. 哈尔滨医药, 2023, 43(5): 7-9.
Li Shujun. Application of Ambroxol Combined with Moxifloxacin In The Treatment of Elderly Patients with Chronic Obstructive Pulmonary Disease in Acute Exacerbation. journal1, 2023, 43(5): 7-9.
链接本文:  
http://www.hrbyybjb.org.cn/CN/10.3969/j.issn.1001-8131.2023.05.003     或     http://www.hrbyybjb.org.cn/CN/Y2023/V43/I5/7
版权所有 © 《哈尔滨医药》编辑部  备案号: 黑ICP备19005758号-1
本系统由北京玛格泰克科技发展有限公司设计开发 技术支持:support@magtech.com.cn